<DOC>
	<DOCNO>NCT02991508</DOCNO>
	<brief_summary>This first clinical trial ADRECIZUMAB . The purpose clinical trial identify safety tolerability different dos ADRECIZUMAB healthy volunteer .</brief_summary>
	<brief_title>Adrecizumab Phase 1 Trial</brief_title>
	<detailed_description>Adrenomedullin ( ADM ) natural occur 52 amino acid peptide mainly express endothelial smooth muscle cell . ADM plasma level increase patient sepsis relate severity disease . ADM key regulator vasotonus endothelial integrity sepsis . ADRECIZUMAB antibody N-terminus ADM partially inhibit bioactivity ADM. Several septic animal study show administration ADRECIZUMAB lead reduce catecholamine demand , improved renal function , improve fluid balance improve survival . The administration ADRECIZUMAB rodents non-human primate ( NHP ) tolerate well . Single dose repeat administration 14 day rat NHP GLP toxicology safety study show clinical side-effects histopathological finding . Based data start dose human being 0.5 mg/kg ADRECIZUMAB single infusion 1 hour increase 8 mg/kg .</detailed_description>
	<criteria>1 . Written inform consent participate trial prior studymandated procedure . 2 . Male subject age 18 35 year inclusive . 3 . Subjects agree use reliable way contraception partner study entry 3 month study drug administration . 4 . BMI 18 30 kg/m² , low limit body weight 50 kg upper limit 100 kg . 5 . Healthy determine medical history , physical examination , vital sign , 12 lead electrocardiogram , clinical laboratory parameter . 1 . Unwillingness abstain medication , recreational drug , antioxidant vitamin supplement course study within 7 day prior treatment day . 2 . Unwillingness abstain smoke alcohol 1 day prior treatment day first 24 hour study . 3 . Surgery trauma significant blood loss blood donation within 3 month prior treatment day . 4 . History , sign symptoms cardiovascular disease , particular : History frequent vasovagal collapse orthostatic hypotension Resting pulse rate ≤45 ≥100 beat / min Hypertension ( RR systolic &gt; 160 RR diastolic &gt; 90 ) Hypotension ( RR systolic &lt; 100 RR diastolic &lt; 50 ) Conduction abnormality ECG consist 1st degree atrioventricular block complex bundle branch block Any chronic cardiac arrhythmia , except PAC 's , PVC 's 5 . Renal impairment : plasma creatinine &gt; 120 µmol/L 6 . Liver function test ( alkaline phosphatase , AST , ALT and/or γGT ) 2x upper limit normal . 7 . History asthma 8 . Atopic constitution 9 . CRP 2x upper limit normal clinically significant acute illness , include infection , within 2 week administration study drug . 10 . Treatment investigational drug participation clinical trial within 30 day prior study drug administration . 11 . Known suspect able comply trial protocol . 12 . Known hypersensitivity excipients drug formulation use . Inability personally provide write informed consent ( e.g . linguistic mental reason ) and/or take part study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adrecizumab</keyword>
	<keyword>Phase 1 clinical trial</keyword>
	<keyword>Adrenomedullin</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Monoclonal recombinant antibody</keyword>
</DOC>